RTA Laboratuvarlari Biyolojik
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, paint… Read more
RTA Laboratuvarlari Biyolojik (RTALB) - Net Assets
Latest net assets as of June 2025: TL2.12 Billion TRY
Based on the latest financial reports, RTA Laboratuvarlari Biyolojik (RTALB) has net assets worth TL2.12 Billion TRY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL2.23 Billion) and total liabilities (TL103.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL2.12 Billion |
| % of Total Assets | 95.35% |
| Annual Growth Rate | 42.72% |
| 5-Year Change | 894.6% |
| 10-Year Change | 3471.14% |
| Growth Volatility | 49.02 |
RTA Laboratuvarlari Biyolojik - Net Assets Trend (2010–2024)
This chart illustrates how RTA Laboratuvarlari Biyolojik's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RTA Laboratuvarlari Biyolojik (2010–2024)
The table below shows the annual net assets of RTA Laboratuvarlari Biyolojik from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL1.67 Billion | +3.23% |
| 2023-12-31 | TL1.62 Billion | +155.52% |
| 2022-12-31 | TL632.74 Million | +84.35% |
| 2021-12-31 | TL343.23 Million | +104.54% |
| 2020-12-31 | TL167.81 Million | +93.56% |
| 2019-12-31 | TL86.69 Million | +51.93% |
| 2018-12-31 | TL57.06 Million | +5.18% |
| 2017-12-31 | TL54.25 Million | +8.06% |
| 2016-12-31 | TL50.20 Million | +7.42% |
| 2015-12-31 | TL46.74 Million | +24.16% |
| 2014-12-31 | TL37.64 Million | +80.69% |
| 2013-12-31 | TL20.83 Million | +89.55% |
| 2012-12-31 | TL10.99 Million | +7.84% |
| 2011-12-31 | TL10.19 Million | -11.10% |
| 2010-12-31 | TL11.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RTA Laboratuvarlari Biyolojik's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14414.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL827.20 Million | 49.56% |
| Other Components | TL841.80 Million | 50.44% |
| Total Equity | TL1.67 Billion | 100.00% |
RTA Laboratuvarlari Biyolojik Competitors by Market Cap
The table below lists competitors of RTA Laboratuvarlari Biyolojik ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
$37.52 Million |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
$37.52 Million |
|
Hyundai E P
KO:089470
|
$37.52 Million |
|
Unictron Technologies Corp
TW:6792
|
$37.53 Million |
|
Toung LoongTextile Mfg Co Ltd
TWO:4401
|
$37.49 Million |
|
Powerwell Holdings Bhd
KLSE:0217
|
$37.49 Million |
|
Kortek Corporation
KQ:052330
|
$37.48 Million |
|
Go Hub Capital Berhad
KLSE:0311
|
$37.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RTA Laboratuvarlari Biyolojik's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,616,784,368 to 1,668,997,057, a change of 52,212,689 (3.2%).
- Net income of 52,234,738 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL52.23 Million | +3.13% |
| Other Changes | TL-22.05K | -0.0% |
| Total Change | TL- | 3.23% |
Book Value vs Market Value Analysis
This analysis compares RTA Laboratuvarlari Biyolojik's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.77x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | TL2.15 | TL3.80 | x |
| 2018-12-31 | TL2.30 | TL3.80 | x |
| 2019-12-31 | TL2.40 | TL3.80 | x |
| 2020-12-31 | TL3.67 | TL3.80 | x |
| 2021-12-31 | TL7.28 | TL3.80 | x |
| 2022-12-31 | TL5.95 | TL3.80 | x |
| 2023-12-31 | TL3.23 | TL3.80 | x |
| 2024-12-31 | TL3.34 | TL3.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RTA Laboratuvarlari Biyolojik utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.94%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.15x
- Recent ROE (3.13%) is below the historical average (15.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 12.36% | 17.16% | 0.54x | 1.34x | TL865.40K |
| 2015 | 16.29% | 22.22% | 0.55x | 1.34x | TL2.89 Million |
| 2016 | 8.19% | 12.85% | 0.52x | 1.22x | TL-904.52K |
| 2017 | 7.68% | 10.81% | 0.61x | 1.16x | TL-1.26 Million |
| 2018 | 1.04% | 2.94% | 0.31x | 1.14x | TL-5.19 Million |
| 2019 | 5.11% | 26.38% | 0.17x | 1.13x | TL-4.24 Million |
| 2020 | 40.55% | 26.44% | 0.90x | 1.71x | TL45.91 Million |
| 2021 | 36.61% | 29.78% | 0.70x | 1.77x | TL83.21 Million |
| 2022 | 47.28% | 326.78% | 0.12x | 1.25x | TL221.66 Million |
| 2023 | -6.38% | -74.48% | 0.08x | 1.12x | TL-264.84 Million |
| 2024 | 3.13% | 32.94% | 0.08x | 1.15x | TL-114.66 Million |
Industry Comparison
This section compares RTA Laboratuvarlari Biyolojik's net assets metrics with peer companies in the Biotechnology industry.
No peer company data available for comparison.